



# A timetable for immediate action

## Who needs to do what, when

| Action  | Main actor   | When  |
|---|--|---|
| Apply non-pharmaceutical public health measures systematically and rigorously in every country at the scale the epidemiological situation requires. All countries to have an explicit strategy agreed at the highest level of government to curb COVID-19 transmission.   | National governments   | Immediately                                       |
| High income countries with a vaccine pipeline for adequate coverage should, alongside their scale up, commit to provide to the 92 low and middle income countries of the Gavi COVAX Advance Market Commitment, at least one billion vaccine doses no later than 1 September 2021 and more than two billion doses by mid-2022, to be made available through COVAX and other coordinated mechanisms.                        | National governments   | Immediately<br>(& no later than 1 September 2021) |
| G7 countries to commit to providing 60% of the US\$ 19 billion required for ACT-A in 2021 for vaccines, diagnostics, therapeutics and strengthening health systems with the remainder being mobilised from others in the G20 and other higher income countries. A formula based on ability to pay should be adopted for predictable sustainable, and equitable financing of such global public goods on an ongoing basis. | G7, G20 and national governments of high-income countries, foundations | Immediately                                       |
| WTO and WHO to convene major vaccine producing countries and manufacturers to get agreement on voluntary licensing and technology transfer arrangements for COVID-19 vaccines (including through the Medicines Patent Pool (MPP)). If actions do not occur within 3 months, a waiver of TRIPS intellectual property rights should come into force immediately.  | WTO, WHO and vaccine-producing countries and manufacturers             | Immediately                                       |
| Production of and access to COVID-19 tests and therapeutics, including oxygen, scaled up urgently in low- and middle-income countries with full funding of US\$ 1.7 billion for needs in 2021 and the full utilization of the US\$3.7 billion in the Global Fund's COVID-19 Response Mechanism Phase 2 for procuring tests, strengthening laboratories and running surveillance and tests.                                | Test- and therapeutics-producing countries and manufacturers / GFATM   | Immediately                                       |
| WHO to develop immediately a road map for the short-term and within three months scenarios for the medium- and long-term response to COVID-19, with clear goals, targets and milestones to guide and monitor the implementation of country and global efforts towards ending the COVID-19 pandemic.   | WHO  | Immediately                                       |